DADr. Agarwals Health Care544350Quarterly results

Board approves Q2 and H1 FY27 results; Dr. Amar Agarwal re-designated Executive Chairman (Whole-Time Director)

Board approved the unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, along with the auditor's limited review report, which carries an unmodified conclusion.

By ScoutQuest · Thu 5 Nov 2026, 6:02 PM IST · 2 min read

H1 FY27 Consolidated Revenue from Operations

INR 1,269 Crores, up 28.7% YoY

H1 FY27 EBITDA

INR 362 Crores, up 27.0% (EBITDA margin 28.2%)

H1 FY27 Profit after Tax

INR 112 Crores, up 50.1% (PAT margin 8.7%)

What the board decided

• Approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the Limited Review Report of M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, the Statutory Auditors.
• Appointed and re-designated Dr. Amar Agarwal, presently Chairman and Non-Executive Director, as Executive Chairman (Whole-Time Director) for a period of three years effective November 01, 2026.
• The company said this follows the Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited becoming effective.
• The terms and conditions of the appointment cum re-designation, and the remuneration payable, remain identical and exact to those already drawn by him at Dr. Agarwal's Eye Hospital Limited, and are subject to the approval of the members.
• Approved a Postal Ballot Notice to seek members' consent for this appointment cum re-designation; the cut-off for e-voting and the e-voting period will be communicated to the exchanges in due course.

Results, as printed (consolidated, unaudited)

• Revenue from Operations, H1 FY27: INR 1,269 Crores, growth of 28.7% year on year.
• EBITDA: INR 362 Crores, growth of 27.0%, with EBITDA margin of 28.2%.
• Profit after Tax: INR 112 Crores, growth of 50.1%, with PAT margin of 8.7%.
• Revenue from Operations for the quarter: INR 655 Crores, growth of 31.4% year on year.
• Profit after Tax for the quarter: INR 57 Crores, growth of 55.8% year on year.

The auditor's review conclusion

• S.R. Batliboi & Associates LLP states that, based on its review and the procedures performed, nothing has come to its attention that causes it to believe the accompanying Statement has not disclosed the information required in terms of the Listing Regulations, or that it contains any material misstatement.
• That is an unmodified conclusion. A review is not an audit and gives moderate, not absolute, assurance.
• The auditor also notes that the figures include unaudited interim results of certain subsidiaries and step-down subsidiaries, reviewed by their respective independent auditors, whose reports were furnished to the statutory auditors.

What this means for a retail reader

• The board meeting delivered two things together: the quarterly and half-year numbers, and a change in who runs the company day to day. Dr. Amar Agarwal moves from a non-executive chair to a full-time executive role.
• Because the pay package mirrors what he drew at the merged entity, the update frames it as a continuation rather than a new, larger remuneration arrangement. The appointment still needs shareholder approval through the postal ballot.
• The financial statements are unaudited and have been reviewed, not audited. The specific line items to track are Revenue from Operations, EBITDA and Profit after Tax, whose growth rates are shown above.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev